TGA gives long-awaited go-ahead for Novavax.
The Therapeutic Goods Administration (TGA) has granted provisional approval for Novavax’s Nuvaxoid COVID-19 vaccines for use in Australia.
The protein subunit vaccine has been approved for use in adults age 18 years and older, with recommendations that it be given in two doses three weeks apart.
An initial shipment of the vaccine is expected to arrive in Australia in February.
More details in today’s issue of Pharmacy Daily.
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
PFIZER Australia’s Vyndamax (tafamidis) is now listed on the PBS for treating fatal heart conditions related to amyloid disorders.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
